LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 146-150

  Lorenzo Betancor, Oswaldo ^a,b   Samaranch, Lluís ^a   Ezquerra, Mario ^c,d   Tolosa, Eduardo ^c,d   Lorenzo, Elena ^a   Irigoyen, Jaione ^a,b,d   Gaig, Carles ^c,d   Pastor, María A ^a,b,d   Soto Ortolaza, Alexandra I ^e   Ross, Owen A ^e   Rodríguez Oroz, María C ^a,b,d   Valldeoriola, Francesc ^c,d   Martí, María J ^c,d   Luquin, María R ^a,b   Perez Tur, Jordi ^d,f   Burguera, Juan A ^g   Obeso, José A ^a,b,d   Pastor, Pau ^a,b,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e MAYO GRADUATE SCHOOL   (United States)

^f INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Dardarin; Genetics; Haplotype; LRRK2; Mutation; Parkinson's disease

Indexed keywords

DIMER; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; RAS PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME 12P; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; EXON; FAMILY STRESS; GENE LOCATION; GENE SEGREGATION; GENE SEQUENCE; GENETIC CONSERVATION; GENETIC SCREENING; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN STABILITY;

ADULT; AGE FACTORS; AGED; ARGININE; CHROMOSOMES, HUMAN, PAIR 12; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; GENETIC LINKAGE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SERINE;

EID: 84855956521     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23968     Document Type: Article

References (30)

1. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54( 11 Suppl 5): S21-23.
2. Munoz E, Pastor P, Marti MJ, Oliva R, Tolosa E A new mutation in the parkin gene in a patient with atypical autosomal recessive juvenile parkinsonism. Neurosci Lett 2000; 289( 1): 66-68.
3. Munoz E, Tolosa E, Pastor P, et al. Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism. J Neurol Neurosurg Psychiatry 2002; 73( 5): 582-584.
4. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365( 9457): 412-415.
5. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365( 9457): 415-416.
6. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005; 365( 9457): 410-412.
7. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44( 4): 595-600.
8. Tan EK, Skipper LM Pathogenic mutations in Parkinson disease. Hum Mutat 2007; 28( 7): 641-653.
9. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44( 4): 601-607.
10. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, Tolosa E LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006; 63( 3): 377-382.
11. Aasly JO, Vilarino-Guell C, Dachsel JC, et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Mov Disord 2010; 25( 13): 2156-2163.
12. Funayama M, Hasegawa K, Ohta E, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005; 57( 6): 918-921.
13. Mata IF, Kachergus JM, Taylor JP, et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005; 6( 4): 171-177.
14. Gorostidi A, Ruiz-Martinez J, Lopez de Munain A, Alzualde A, Masso JF LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 2009; 10( 2): 157-159.
15. Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005; 128( Pt 12): 2786-2796.
16. Haugarvoll K, Wszolek ZK Clinical features of LRRK2 parkinsonism. Parkinsonism Relat Disord 2009; 15 Suppl 3: S205-208.
17. Marder K, Levy G, Louis ED, et al. Accuracy of family history data on Parkinson's disease. Neurology 2003; 61( 1): 18-23.
18. Guerreiro RJ, Baquero M, Blesa R, et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging 2010; 31( 5): 725-731.
19. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005; 76( 4): 672-680.
20. Bosgraaf L, Van Haastert PJ Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 2003; 1643( 1-3): 5-10.
21. Ito G, Okai T, Fujino G, et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry (Mosc) 2007; 46( 5): 1380-1388.
22. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 2008; 105( 5): 1499-1504.
23. Daniels V, Vancraenenbroeck R, Law BM, et al. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 2011; 116( 2): 304-315.
24. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7( 7): 583-590.
25. Ishihara L, Gibson RA, Warren L, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord 2007; 22( 1): 55-61.
26. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006; 354( 4): 422-423.
27. Change N, Mercier G, Lucotte G Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects. Genet Test 2008; 12( 3): 333-339.
28. Adams SM, Bosch E, Balaresque PL, et al. The genetic legacy of religious diversity and intolerance: paternal lineages of Christians, Jews, and Muslims in the Iberian Peninsula. Am J Hum Genet 2008; 83( 6): 725-736.
29. Lorenzo-Betancor O, Samaranch L, Garcia-Martin E, et al. LINGO1 gene analysis in Parkinson's disease phenotypes. Mov Disord 2011; 26( 4): 722-727.
30. Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008; 70( 16 Pt 2): 1403-1410.